Form 4: Vaxcyte Executive Jim Wassil Receives Performance-Based Stock Options and Restricted Stock Units

Jim Wassil, Chief Operating Officer of Vaxcyte, Inc., was granted performance-based stock options and restricted stock units on November 7, 2024, subject to service and performance vesting conditions.

Summary

• On November 7, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc., received a grant of performance stock options to purchase 87,481 shares of Vaxcyte's common stock at an exercise price of $102.70 per share.
• These options vest in three equal installments on the third, fourth, and fifth anniversaries of the grant date, contingent on continued service.
• A performance-vesting condition also requires Vaxcyte's common stock to average at least $154.05 over a one-year period.
• Wassil also received 35,661 performance restricted stock units (PSUs), each representing the right to receive one share of Vaxcyte's common stock.
• The number of shares ultimately delivered for the PSUs will depend on Vaxcyte's total shareholder return (TSR) percentile rank within a peer group over a four-year period, ranging from 0% to 250% of the target number of shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices with performance-based incentives, which is generally viewed positively. The sentiment is neutral to slightly positive.

Positives

• The performance-based awards align executive compensation with company performance and shareholder value.
• The vesting conditions incentivize long-term service and achievement of specific financial goals.

Risks

• The performance vesting conditions may not be met, resulting in the forfeiture of some or all of the stock options and PSUs.
• The value of the stock options and PSUs is subject to market fluctuations and the performance of Vaxcyte's stock.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules and performance conditions of the equity awards.

Industry Context

Performance-based compensation is a common practice in the biotechnology industry to incentivize executives to achieve specific milestones and increase shareholder value. The use of TSR as a performance metric aligns executive compensation with the returns received by shareholders.

Comparison to Industry Standards

• Many biotech companies use a combination of stock options and restricted stock units with performance-based vesting conditions.
• Peer groups for TSR comparisons often include companies with similar market capitalization, therapeutic focus, and stage of development.
• The specific TSR percentile rank targets and payout ranges vary depending on the company and its compensation philosophy.

Stakeholder Impact

• Shareholders: The performance-based compensation structure aims to align management's interests with shareholder value creation.
• Employees: The company-wide grant of performance stock options suggests a broader effort to incentivize employees and align their interests with the company's success.

Key Dates